Lacipil

Lacidipine, the active ingredient in Lacipil, is a calcium channel blocker presented as an oral tablet for oral use. It lowers elevated blood pressure by relaxing vascular smooth muscle and is indicated for the management of hypertension in adult patients.

GNH USA supplies Lacipil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global markets. Our network ensures timely delivery and regulatory support across Europe, Asia, Africa and the Americas.

Lacidipine is a dihydropyridine calcium channel blocker used to treat hypertension and related blood‑pressure disorders. - Essential hypertension: lowers blood pressure in patients with primary hypertension. - Isolated systolic hypertension: reduces elevated systolic pressure in older adults. - Diastolic hypertension: helps control high diastolic pressure.

Lacidipine may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Headache: mild to moderate headache occurring shortly after dosing. - Flushing: transient facial warmth and redness. - Peripheral edema: swelling of ankles or feet due to fluid accumulation. - Dizziness: light‑headed sensation, especially when standing quickly.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Angioedema: swelling of lips, tongue or airway requiring urgent care. - Myocardial infarction: rare occurrence of heart attack.

When prescribing Lacidipine, clinicians should consider several precautionary measures to ensure safe use. - Dose adjustment: reduce dose in patients with hepatic impairment. - Concomitant therapy: avoid use with strong CYP3A4 inhibitors. - Orthostatic hypotension: monitor blood pressure when initiating therapy. - Pregnancy: safety not established; avoid use unless benefit outweighs risk. - Elderly patients: start at low dose and titrate cautiously. - Store at ambient temperature: keep tablets below 25°C in original container, protect from moisture.

Lacidipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Lacidipine plasma levels. - Grapefruit juice: can markedly raise drug concentration leading to hypotension.

Moderate Interactions (Monitor Closely): - Other antihypertensives (e.g., ACE inhibitors, diuretics): risk of additive blood pressure lowering. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce Lacidipine effectiveness. - Beta‑blockers: monitor for excessive bradycardia or hypotension.